Keryx, Aeterna soar on 'fast-track' designation
April 05, 2010 at 11:29 AM EDT
Keryx Biopharmacueticals rallies as U.S. regulators granted “fast-track” status to the company’s oncology drug candidate, with fellow small-cap Aeterna also on the move higher.